Tumour lysis syndrome in haematological malignancies
Related Experiment Video
Updated: Sep 16, 2026

Capture and Release of Viable Circulating Tumor Cells from Blood
Published on: October 28, 2016
B van der Hoven1, P L Thunnissen, W Sizoo
1Department of Haematology, Daniël den Hoed Cancer Centre, Rotterdam, Netherlands.
Abstract:
The tumour lysis syndrome, a combination of metabolic derangements, is a complication of intensive cytotoxic chemotherapy, especially in rapidly proliferating lymphoid malignancies. During the last three years we have encountered four cases with different forms of haematological neoplasms, all of whom developed tumour lysis, i.e. some degree of hyperuricaemia, hyperkalaemia, hyperphosphataemia or hypocalcaemia, resulting in renal, circulatory and/or respiratory failure. Relevant literature is reviewed.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

